当前位置: X-MOL 学术Pharmacogenomics J. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Prospective validation of the International Warfarin Pharmacogenetics Consortium algorithm in high-risk elderly people (VIALE study).
The Pharmacogenomics Journal ( IF 2.8 ) Pub Date : 2019-12-05 , DOI: 10.1038/s41397-019-0129-6
Amelia Filippelli 1, 2 , Simona Signoriello 3 , Ciro Bancone 4 , Graziamaria Corbi 5 , Valentina Manzo 1, 2 , Severino Iesu 6 , Cecilia Politi 5 , Alberto Gigantino 7 , Maria Teresa De Donato 8 , Paolo Masiello 6 , Vittorio Simeon 3 , Alessandro Della Corte 9 , Michele Cellurale 10 , Valeria Conti 1, 2 , Massimo Frigino 11 , Tiziana Ciarambino 12 , Marta Marracino 8 , Laura Carpenito 1 , Nicola Ferrara 10 , Marisa De Feo 9 , Ciro Gallo 3
Affiliation  

We assessed the predictive accuracy of the Warfarin Pharmacogenetics Consortium (IWPC) algorithm in a prospective cohort of 376 high-risk elderly patients (≥65 years) who required new treatment with warfarin for either medical (non valvular atrial fibrillation) or surgical conditions (heart valve replacement), had ≥1 comorbid conditions, and regularly used ≥2 other drugs. Follow-up visits were performed according to clinical practice and lasted for a maximum of 1 year. Two hundred and eighty-three (75%) patients achieved a stable maintenance dose. Warfarin maintenance doses were low on average (median 20.3 mg/week, interquartile range, 14.1–27.7 mg/week) and were substantially overestimated by the IWPC algorithm. Overall the percentage of patients whose predicted dose of warfarin was within 20% of the actual stable dose was equal to 37.5%, (95% CI 32.0–43.3%). IWPC algorithm explained only 31% of the actual warfarin dose variability. Modifications of the IWPC algorithm are needed in high-risk elderly people.



中文翻译:

国际华法林药物遗传学联合会算法在高危老年人中的前瞻性验证(VIALE研究)。

我们评估了376名高危老年患者(≥65岁)的前瞻性队列中华法林药物遗传学联合会(IWPC)算法的预测准确性,这些患者需要在医学上(非瓣膜性心房颤动)或手术条件(心脏)进行华法林新治疗瓣膜置换术),≥1种合并症,并定期使用≥2种其他药物。根据临床实践进行随访,随访时间最长为1年。283名(75%)患者达到了稳定的维持剂量。华法林维持剂量平均较低(中位数为20.3 mg /周,四分位间距为14.1–27.7 mg /周),并且被IWPC算法大大高估了。总体上,华法林的预测剂量在实际稳定剂量的20%以内的患者所占的百分比等于37.5%,(95%CI 32.0–43.3%)。IWPC算法仅解释了实际华法林剂量变异性的31%。高危老年人需要修改IWPC算法。

更新日期:2019-12-05
down
wechat
bug